Background: The influence of dexmedetomidine on postoperative delirium (POD) in adult surgical patients remains controversial. We aimed to analyse whether dexmedetomidine use could decrease POD incidence in this population and its relation to timing of dexmedetomidine administration and patient age. Methods: We used random-effects modelled meta-analysis, trial sequential analysis, and followed Cochrane methodology with Grading of Recommendations Assessment, Development, and Evaluation (GRADE). PubMed and Cochrane library were searched up to July 2017 for randomised controlled trials that analysed POD incidence of adult surgical patients (age !18 yr) after dexmedetomidine administration. Results: Eighteen studies (comprising 3309 patients) were included. There was decreased risk of POD with dexmedetomidine use for the entire adult surgical population [odds ratio (OR) 0.35; 95% confidence interval (CI) 0.24e0.51)], with firm evidence from trial sequential analysis. Pre-specified subgroup analyses confirmed this result with firm evidence for cardiac and non-cardiac surgical patients, (OR 0.41; 95% CI 0.26e0.63) and (OR 0.33; 95% CI 0.18e0.59), respectively. We also found firm evidence for reduction of POD if dexmedetomidine is administered during the postoperative period (OR 0.30; 95% CI 0.21e0.44), in patients aged <65 yr (OR 0.19; 95% CI 0.10e0.36) or !65 yr (OR 0.44; 95% CI 0.30e0.65). Evidence for dexmedetomidine's influence on secondary outcomes (in-hospital mortality, intensive care unit and hospital length of stay, bradycardia, and hypotension) is thus far insufficient to draw conclusions. Conclusion: Dexmedetomidine can reduce POD incidence for adult cardiac and non-cardiac surgical patients. The optimal dose and timing of dexmedetomidine and influence on other outcomes or particular patient populations with risk factors warrants further studies.
Postoperative delirium is common, particularly in elderly patients, and is associated with worse outcomes. In this meta-analysis of randomised trials of dexmedetomidine in adult surgical patients, dexmedetomidine use significantly reduced the incidence of postoperative delirium. Efficacy was similar for younger and older adults, and for intra-or post-operative administration.
Postoperative delirium (POD) incidence reaches up to 51% after surgery. 1 Elderly patients aged 65 yr and older are at greatest risk. 2 POD is distressing for patients and their families, and has been associated with higher morbidity and mortality, prolonged length of hospital stay, and increased healthcare costs. 3 Dexmedetomidine is a highly selective a 2 -adrenergic receptor agonist, which provides anxiolysis, sedation, and modest analgesia with minimal respiratory depression. 4, 5 Although dexmedetomidine has some unique pharmacodynamic properties, its effects on delirium remain controversial. 6, 7 Recently, some meta-analyses concentrated on the use of dexmedetomidine to prevent delirium for adults who stayed in ICU without distinction between surgical and nonsurgical patients. These meta-analyses showed that dexmedetomidine administration on ICU could reduce delirium incidence. 8, 9 Other meta-analyses focused on adult patients undergoing cardiac surgery. 10, 11 There are few data for noncardiac surgical patients and perioperative use of dexmedetomidine. Therefore, we performed a meta-analysis of randomised controlled trials to address the hypothesis whether dexmedetomidine in adult patients decreases POD incidence in a general surgical population. Furthermore, we aimed to assess the effect of timing of dexmedetomidine administration and age of patients on POD incidence.
Methods

Protocol and registration
The study protocol has not been published previously. The manuscript has been prepared according to the PRISMA (Preferred Reporting Items for Systematic reviews and MetaAnalyses) statement. 12 Our study was registered in the PROS-PERO database: CRD42017072380.
Eligibility criteria
Exclusion and inclusion criteria were defined before carrying out the meta-analysis: only human randomised controlled trials in adult surgical patients (age !18 yr) that addressed POD incidence, administered dexmedetomidine, and were published from inception of databases until July 22, 2017, were included. Subgroup analyses were planned for POD incidence depending on the type of surgery (cardiac and non-cardiac), dexmedetomidine administration at intraoperative period (during surgery), postoperative period (after surgery) and perioperative period (during surgery and after surgery), different diagnostic tools for delirium assessment, and age. As secondary outcomes we examined in-hospital mortality, 30 day mortality, delirium duration, length of ICU stay, length of hospital stay, length of mechanical ventilation (MV), time to extubation, bradycardia, hypotension, tachycardia, and hypertension. Non-randomised clinical trials, case series, and systematic reviews were excluded. Studies of English and Chinese language were included in the search.
Information sources and search
A systematic search was performed until July 2017 via PubMed and Cochrane library. Search term "dexmedetomidine and delirium" was used in both databases. Full search strategy for Study selection and data collection X.D. and A.K. extracted data independently and meta-analyses were performed according to predefined study selection criteria and clinical end points. Disagreements on data abstraction and quality assessment between X.D. and A.K. were resolved by J.V.W. Two authors (Dong-Xin Wang, personal communication, 2017; George Djaiani, personal communication, 2017) were contacted to provide us with their results regarding POD incidence in patients, whose age was above 80 yr.
13,14
Data items
We extracted the data summarised in Table 1 34, 35 Odds ratio (OR) and 95% CI were calculated for dichotomous outcomes. Continuous outcomes were calculated by weighted mean differences (WMD) of mean values and standard deviations. A P value <0.05 was assumed as statistically significant. We created funnel plots to determine publication bias if at least 10 trials were identified. Low sample sizes and repeated significance testing of included studies in meta-analyses might result in an increased risk of random errors. 36 Therefore, we performed a trial sequential analyses (TSA) by TSA software version 0.9 beta software, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark (http://www.ctu.dk/ tsa). 37 TSA offers the possibility to evaluate the credibility of statistical results from our meta-analyses. TSA was used to decide whether CI and P values in meta-analyses are sufficient to show anticipated effect. 38 We calculated required information size (IS) adjusted for our meta-analysis and trial sequential monitoring boundaries (TSMB) that determine whether the evidence in our meta-analysis is reliable and conclusive. 39 If the cumulative Z-curve entered the futility area or crossed TSMB, anticipated intervention effect showed firm evidence. Otherwise, evidence was rated as absent. For dichotomous outcomes we have set effect measure 'Odds Ratio' and model as 'Random-effects (DL)' in TSA software. For our sensitivity analyses we used different models of TSA. D 2 (diversity) was defined as heterogeneity correction. For the total POD incidence, nine TSA models were used to assess the meta-analysis evidence in a sensitivity analysis.
These models included an assumed type-1 error a of 5% and 1%, and a pre-defined power (1eb) of 80% and 90% in each model. Other data were calculated from average incidence in all included studies or low risk of bias studies. Otherwise, relative risk reduction was defined as 30%, D 2 was defined as 25%, 50%, and 75%. We have fixed one of these nine models with a type-1 error a of 5% and a power (1eb) of 80% for other outcomes in our study: for dichotomous data, we calculated required IS based on the incidence in low risk of bias studies; for continuous data, we estimated required IS based on D 2 as 50%, and mean difference and variance based on empirical assumptions, which are autogenerated by the software. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the quality of evidence, which was classified as high, moderate, low or very low. Judgments included risk of bias, inconsistency, indirectness, imprecision and other considerations. GRADE Proversion 3.6 software, McMaster University, Hamilton, Ontario, Canada (http://gradepro.org/) was used.
Results
Study selection
Search in PubMed and Cochrane library identified 422 studies. Forward reference searching in Google scholar and first-level backward searching in relevant reviews and meta-analyses revealed 17 additional studies. After removing duplicates, we screened 336 studies on the basis of abstracts. Finally, 81 full text articles were assessed for eligibility. In total, 18 studies could be included in our analysis ( Supplementary Fig. S1 ).
Study characteristics/participants
Overall, data from 3309 patients were analysed in this systematic review and meta-analysis, 1616 patients received dexmedetomidine and 1693 patients received other drugs or saline. Dexmedetomidine dosages (with or without loading dose) and duration of administration varied (Table 1) Dexmedetomidine duration of administration was reported in some studies, the minimum duration was 2 h 17 and maximum duration was nearly 24 h. 15 In other studies dexmedetomidine was administered during surgery, 22 during MV, 16, 19, 28 before extubation, 13, 21 or until next morning. 7 Here, exact duration of administration was unobtainable. The largest study included 700 patients and the smallest one 58 patients, 7, 20 (Table 1) . Some non-cardiac surgical studies included different surgical procedures (orthopaedic, thoracic, spine, abdominal, lower limb, or minor other surgeries), 7, 17, 19, 28 but did not report the outcomes separated for each procedure (Table 1) . A cardiopulmonary bypass was used in all cardiac surgery studies but one, which did not use it in all their patients. 14 
Risk of bias within and across studies
Overall quality of the studies was moderate. Random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias of each included study are described in Supplementary Table S2 .
Pooled results of included studies
Primary outcome: POD incidence
Meta-analysis with 3309 patients of all included studies 7,13e29 showed that dexmedetomidine was associated with a significant reduction in POD incidence (OR 0.35; 95% CI 0.24e0.51, P<0.01, I 2 ¼53%; Fig. 1a ). Funnel plot for the total POD incidence did not suggest the presence of publication bias ( Supplementary Fig. S2 ). Individual study results for POD are shown in Supplementary Table S3 . Z-curves of the nine 2 ¼72%) for non-cardiac surgery, favouring dexmedetomidine (Fig. 1a) . TSA analysis using the defined model, which was previously described in methods, showed that the number of participants reached the IS and Zcurve crossed TSMB in 'cardiac surgery' subgroup; required information size was not reached in 'non-cardiac surgery' subgroup, but Z-curve crossed TSMB. Therefore, TSA revealed firm evidence for anticipated intervention effect for each subgroup (Fig. 1b and c, Table 3 ). The GRADE-rated evaluation showed high and moderate quality of evidence for cardiac and non-cardiac surgery, respectively (Supplementary Table S4 ).
Additional subgroup analyses were performed for different periods of study treatment administration. We have identified 375 patients in three studies, 20 Fig. S3 ). There was no significant difference in POD incidence when dexmedetomidine was used during perioperative period (during surgery and after surgery) in three related studies with 754 patients 14, 17, 19 (OR 0.87; 95% CI 0.56e1.36, P¼0.55, I 2 ¼0%).
Pooled results for dexmedetomidine administration period are presented in Figure 2a . TSA showed that the Z-curves did not cross the TSMB or the futility boundary, which revealed absence of evidence for anticipated intervention effect when dexmedetomidine was used during intraoperative period and perioperative period ( Fig. 2b and d) . Firm evidence was only found for anticipated intervention effect in postoperative period ( Fig. 2c ) with moderate quality of evidence (downgraded for low proportion of low risk of bias studies; Supplementary Table S4 ). TSA showed firm evidence for both age groups ( Fig. 3b and c) . Of note, nine studies were assigned to the age groups based on the mean age of the patients in the respective study and not the exact age, due to insufficient information. 13e16,23e26, 29 We could not identify enough studies to perform the pre-specified subgroup analysis for patients above 80 yr.
Secondary outcomes
Results of individual studies for the secondary outcomes are presented in Supplementary Table S5 . Four studies of 961 patients 13, 16, 17, 27 examined in-hospital mortality rate. There was no significant difference (OR 0.62; Table 2 Trial sequential analysis for postoperative delirium incidence with nine models of all included studies. D 2 , diversity; FB, futility boundary; FE, firm evidence; ICA, incidence in control arm; IIA, incidence in intervention arm; IS, information size; RRR, relative risk reduction; TSMB, trial sequential monitoring boundary. Error a was defined as 5% and 1%, 1eb was defined as 80% and 90% separately in each model; A and B, IIA and ICA were calculated from the average incidence in intervention group and control group separately in all included studies; C, RRR% was defined as 30%, ICA was calculated from the average incidence in control group of all included studies; D and E, IIA and ICA were calculated from the average incidence in intervention group and control group separately in all low risk of bias studies; F, RRR% was defined as 30%, ICA was calculated from the average incidence in all low risk of bias studies; G, H, and I, IIA and ICA were calculated from the average incidence in intervention group and control group separately in all low risk of bias studies, heterogeneity corrections were defined 25%, 50%, and 75%, separately 95% CI 0.19e1.98, P¼0.42, I 2 ¼2%) between the groups. However, studies are lacking firm evidence in TSA (Table 3) . Quality of evidence was judged to be low in consequence of imprecision with a percentage of the required IS of 26% (Supplementary  Table S6 ). Four studies including 399 participants 15, 23, 24, 29 reported length of ICU stay as mean values and standard deviation and were therefore included in a meta-analysis. There was no significant difference (WMD e1.14 h; 95% CI e5.90 to 3.61, P¼0.64, I 2 ¼74%), but TSA showed absence of evidence for this result (Table 3 ). In addition, GRADE quality of evidence was very low due to serious risk of bias, inconsistency and imprecision (Supplementary Table S6 ). Three studies 15, 23, 24 with 320 patients were included in a meta-analysis for length of hospital stay. It revealed no significant difference (WMD e0.34 days; 95% CI e1.68 to 1, P¼0.62, I 2 ¼60%), while lacking of firm evidence by TSA (Table 3) and very low quality (Supplementary Table S6 Table S6 ).
The same five cardiac surgery studies 14, 15, 21, 24, 27 showed that there was no difference in hypotension incidence (OR 0.85; 95% CI 0.44e1.63, P¼0.62, I 2 ¼72%). This was in contrast to the six non-cardiac surgery studies, 7,17e19,28,29 which revealed that dexmedetomidine increased hypotension incidence (OR 1.46; 95% CI 1.05e2.03, P¼0.02, I 2 ¼22%). However, we revealed lack of evidence and a very low quality of evidence (GRADE) for both results (Table 3 and Supplementary Table S6) . Of note, the definitions of bradycardia and hypotension in each trial are presented in Supplementary Table S5 and showed a huge variability.
Other pre-specified secondary outcomes
Results of individual studies reporting these outcomes are presented in Supplementary Table S5 . Meta-analyses could not be reasonably performed for these outcomes due to the low numbers of studies: only two studies were identified that reported the 30-day mortality or mean values and standard deviations for delirium duration. Length of MV and time to extubation were reported in fewer three studies.
Discussion
Our meta-analysis revealed that dexmedetomidine could decrease the risk of POD for adult surgical patients with firm evidence from TSA. Besides cardiac surgical patients, it also significantly reduces POD incidence of non-cardiac surgical patients. In addition, dexmedetomidine appears to benefit younger and elderly patients. Furthermore, POD incidence could be decreased when dexmedetomidine is administered solely during the postoperative period.
The European Society of Anaesthesiology suggested that dexmedetomidine might be considered to decrease POD incidence after cardiac or vascular surgery, 40 but no suggestions were made for non-cardiac surgical patients. Therefore, we performed a separate subgroup analysis for cardiac and noncardiac surgery. Our subgroup analysis confirmed the result of a recent meta-analysis, 10 which showed a decreased risk of POD after dexmedetomidine administration in cardiac surgery. Additionally, our meta-analysis of nine non-cardiac surgical studies 7,17e20,22,25,28,29 revealed that dexmedetomidine decreases POD incidence. Although the TSA showed that the required IS was not reached for this meta-analysis, the Zcurve surpassed the TSMB for benefit. This means that the statistical significance was reached to detect a certain intervention effect for dexmedetomidine in this subgroup. 37 Of note, our result was accompanied by a significant interstudy heterogeneity (I 2 ¼72%). One of the non-cardiac studies played an important role in this significant heterogeneity. 17 This study showed low risk of bias with 390 included patients and reported no difference in POD between the dexmedetomidine and saline group. One explanation could be that this was one of two non-cardiac surgical studies, 17, 19 which has administered study medication during the perioperative period, but only for 2 h after surgery resulting in a total duration of about 3 h. This is a short duration in contrast to five studies, which administered dexmedetomidine until the next morning, 7, 29 for >11 h 18, 28 or during the whole MV duration. 19 Also, they did not administer a loading dose unlike a non-cardiac study, which used dexmedetomidine solely during surgery. 25 Thus, the different conclusion of Deiner and colleagues 17 might have an origin in a lower total dose of dexmedetomidine. Furthermore, this study revealed a high proportion of patients with mild cognitive impairment at baseline, and excluded patients with ASA classification of >III or planned postoperative admission to ICU. 17 Another explanation could refer to the risk of bias in the analysed studies, as three of them 18, 19, 28 (comprising 464 patients) showed high or unclear risk for selection, performance, and detection bias. However, TSA showed firm evidence and a moderate quality was rated by GRADE. Therefore, we suggest that dexmedetomidine should be considered for use in cardiac and non-cardiac surgical patients for prevention of POD. At present, comments about the optimal dose cannot be finally concluded from our included studies. Based on our approach, which considered only the studies with the primary endpoint of 'delirium incidence', it seems that starting with either no loading dose or up to 0.5 mg kg À1 followed by a maintenance dose of 0.2 mg kg À1 h À1 might be the optimal choice. Of note, the mean value of the applied maintenance dose of dexmedetomidine was not reported in any study and the quality of the studies was heterogeneous. Therefore, a reliable optimal dose is one of the remaining questions, which needs to be addressed in future research. Additionally, we assessed different periods of dexmedetomidine administration. We revealed that dexmedetomidine is significantly associated with a decreased POD incidence when administered solely intraoperatively during surgery 20, 22, 25 or after surgery. 7,13,15,16,18,19,21,23,24,26e28 However, there was no significant difference in POD incidence in studies, which have administered dexmedetomidine during and after surgery. 14, 17, 29 This may be due to absence of evidence for anticipated intervention effect for intra-and perioperative period subgroups and a low GRADE quality of evidence in both subgroups. Therefore, more high-quality studies are needed to assess optimal timing of dexmedetomidine administration. We could show that 12 of 18 included studies used the CAM or CAM-ICU to detect postoperative delirium. 7,13,14,17e19,21,22,24,25,27,29 CAM-ICU is known for its high validity and reliability for detection of ICU delirium (sensitivity 81% and specificity 96%). 41 However, two studies 23, 26 used different tools and, worse, four studies did not mention their assessment tools. 15, 16, 20, 28 Patients above 80 yr will be the most rapidly increasing group among surgical admissions in the future and advanced age is known as an important risk factor for POD. 40, 42 We tried to pool the effect of evidence for patients aged !80 yr, but limited data impeded the conduct of a meta-analysis. Thus, further investigations are needed to address this relevant topic. Nevertheless, our meta-analyses revealed with firm and moderate quality of evidence that dexmedetomidine decreased POD incidence for patients !65 yr and <65 yr. This is important, as POD is not only common in the elderly patients. It can occur in patients of any age, depending on the precipitating risk factors. 40 Of note, our age classification based on the reported mean age values in several studies and may have induced some misclassification. Further important risk factors for POD include: comorbidities, ASA score; preoperative medications; metabolic disorders; pre-existing cognitive decline; surgery duration; site of surgery; intraoperative bleeding; and pain. 40 Most included patients often revealed a combination of these risk factors and it was not possible to retrieve the delirium incidences separated for patients according to their risk factors. Only two studies presented a comparison of patients with and without POD, irrespective of the treatment group. 13, 17 They reported: a higher POD incidence for patients with advanced age; longer surgery or cardiopulmonary bypass time; orthopaedic, spine, and urological surgery; pre-existent cognitive impairment; and lower educational level. More studies are needed, to identify particular patient groups, who would gain the most benefit from dexmedetomidine administration. Alleviation of pain, particularly with some opioids, is known to promote both delirium and postoperative cognitive loss. 43 Additionally, type of sedation in critically ill patients is associated with an increased risk of delirium. Dexmedetomidine reduced delirium rates in critically ill patients when compared with midazolam. 8 The included studies that administered opioids or narcotics, 16,19,21,23e25,27,28 showed that dexmedetomidine reduced delirium incidence in comparison with remifentanil, 24 propofol, 23 ketamine, 25 and midazolam. 23, 28 In addition, we investigated in-hospital mortality, length of ICU stay and length of hospital stay. However, several of continuous outcomes were reported as median value, 95% CI and inter-quartile range instead mean values and standard deviation. These data should be used cautiously in metaanalyses as they are usually not normally distributed values.
30,31 Therefore, we did not transform these values into standard deviations, which resulted in only a few available studies for the meta-analyses. Thus, our TSA showed an absence of evidence for these outcomes due to a failure to reach the required IS. Consequently, it is impossible to make any conclusion from these results, unless more high-quality studies are available. Data for 30-day mortality, delirium duration, time of MV, and time to extubation were sparse and measurements were not standardised, which impeded pooling of these results. Furthermore, our TSA and GRADE analyses demonstrated that it is currently unreasonable to draw a conclusion regarding the relationship of dexmedetomidine and the adverse events bradycardia or hypotension. TSA showed an absence of evidence for the effect on hypotension in both types of surgery subgroups and bradycardia in the cardiac surgery subgroup. The TSA result of firm evidence for 'no difference' in bradycardia incidence in the non-cardiac surgery subgroup was of low quality.
Limitations
This systematic review and meta-analysis has several potential limitations. First, seven of the included studies had a sample size of <100 patients, which are typically characterised as small studies. As a result, our study may be subject to small study effect bias. 44 Second, we did not investigate all outcomes related to the use of dexmedetomidine. Instead, we collected and analysed outcomes for dexmedetomidine, which are frequently reported. Therefore, some occasionally reported outcome variables were not included in our meta-analysis, such as pain, discomfort, anxiety, and vomiting. Third, for dichotomous data, we calculated required IS based on the incidence in low risk of bias studies. As a result, our conclusions depend on the studies of low risk of bias. However, eight studies had high risk of bias, which corresponds to 44% of all included studies; therefore, our selected TSA model might not be objective enough, due to lack of low risk of bias studies in some subgroup meta-analyses. Fourth, seven studies did not focus on POD as their primary outcome. Instead, outcomes, such as renal function, VAS pain scores, patient's satisfaction, microcirculatory variables, were evaluated primarily. Therefore, our extracted data might have been incidental findings in these articles. Additionally, we collected some of our data by contacting corresponding authors. Unfortunately, only two authors provided results regarding POD incidence in patients, whose age was above 80 yr. Also, duration and dosage of dexmedetomidine varied markedly between studies and we cannot exclude an influence of these on our results. Finally, TSA has its own limitation, as an array of models can be used to assess the evidence of meta-analyses. Differences in assumptions regarding effect size estimates, event proportions, and D 2 lead to different IS, and influence whether the Z-curve will cross TSMB. Therefore, our conclusions of TSA depend on our assumptions and the predefined variables in the used models. Thus, using calculated incidence rates from low risk of bias studies in the TSA model may be inappropriate for subgroup analyses with a low proportion of low risk of bias studies, such as the POD incidence after treatment during the postoperative period or in patents aged <65 yr. Also, we acknowledge that our TSA results have always to be considered with the quality of evidence. In our analysis, the quality of evidence was only high for the use of dexmedetomidine in cardiac surgery and the use of the CAM-ICU assessment tool. Further research is likely to have an important impact on our confidence in the estimate of effects and is likely to change the estimate for our outcomes with low quality. Precise effects of dexmedetomidine on outcomes such as in-hospital mortality, bradycardia, and hypotension incidence remain unclear.
Conclusion
Dexmedetomidine could reduce POD incidence for cardiac and non-cardiac surgical patients, administered in postoperative period and for patients aged !65 or <65 yr, with firm evidence from our chosen TSA model. Nevertheless, we think that further large high-quality standardised studies with POD as primary endpoint are needed to explore the optimal dose of dexmedetomidine and the potentially important effect of intraoperative dexmedetomidine administration, also in noncardiac surgery. Additionally, we require the elucidation of patient populations with vulnerable risk factors, who would particularly benefit from dexmedetomidine administration. Future studies should also focus on the effect of
